In a historic policy shift, the U.S. Food and Drug Administration (FDA) has officially issued a direct final rule updating its regulations to clarify that non-animal testing methods can be used to evaluate the safety of new drugs. Thanks to major advances in biotechnology, pharmaceutical companies can now utilize alternative methods like human cell models, organs-on-chips, and complex computer simulations before human clinical trials. This landmark decision marks a massive step forward in replacing traditional animal models with advanced, high-tech human biology alternatives.
About the Author
